Acquired Cord Blood CariCord was acquired by Celularity in 2018, indicating a potential alignment with Celularity’s broader portfolio in immuno-oncology and placental cell therapeutics. Sales teams can explore partnership or cross-sell opportunities with Celularity’s network and customer base.

Public-Private Venture Operates as a private cord blood bank in collaboration with the University of Colorado, leveraging an FDA-licensed processing lab and in-house expertise. This suggests credibility with hospital systems and potential bids for institutional storage contracts or research collaborations.

Clean Room Excellence Processing in a class 10,000 clean room using standard cord blood manufacturing processes. This strong quality control position can be highlighted when selling to clinics and transplant centers seeking validated, high-quality cord blood banks.

Experience and Scale Signals Over 18 years of processing with numerous releases for transplant, though current employee count is small. Opportunities may exist to engage via preferred vendor programs with larger healthcare networks seeking established workflow and reference cases.

Tech and Marketing Footprint Active web presence with multiple marketing tech tools and a modest revenue range. Use these signals to tailor outreach with digital-led campaigns, partner co-marketing, and demonstrations of scalable processing capabilities to potential purchasers or partners.